Allergan Finance LLC 8-K 2011
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
May 13, 2011
WATSON PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Registrants telephone number, including area code: (862) 261-7000
(Former name or former address, if changed since last report): Not applicable.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
TABLE OF CONTENTS
(e) On May 13, 2011, Watson Pharmaceuticals, Inc. (the Company) held its 2011 Annual Meeting of Stockholders (the Annual Meeting) in Parsippany, NJ. At the Annual Meeting, the Companys stockholders approved the Fourth Amendment and Restatement of the Companys 2001 Incentive Award Plan (the Plan). As a result of such amendment and restatement: (a) the aggregate number of shares authorized for issuance under the Plan after December 31, 2010 shall not exceed 8,241,885 shares; (b) the share counting methodology used for purposes of determining the number of shares available for issuance pursuant to awards under the Plan has been revised; (c) the range of performance criteria that may be used in connection with certain performance-based awards under the Plan has been expanded; (d) the term of the Plan has been extended until 2021; and (e) various administrative provisions contained in the Plan were clarified.
The foregoing summary of the Fourth Amendment and Restatement of the Plan is qualified in its entirety by reference to the full text of the document, which was filed with the Securities and Exchange Commission as Appendix B to the Companys 2011 Proxy Statement dated April 1, 2011 (the 2011 Proxy Statement) and the terms and conditions of which are incorporated herein by reference.
Item 5.07 Submission of Matters to a Vote of Security Holders.
The Companys stockholders voted to approve an amendment and restatement of the Companys Articles of Incorporation which, among other things, provides for the declassification of the Companys Board of Directors and the deletion of certain other provisions, as described in the 2011 Proxy Statement, with voting results as follows:
As described under Item 5.02 above, the Companys stockholders voted to approve the Fourth Amendment and Restatement of the Plan, with voting results as follows:
The Companys stockholders voted to approve, on an advisory basis, the compensation of the Companys named executive officers, as such compensation was described in the Compensation Discussion and Analysis, compensation tables and narrative discussion set forth in the Companys 2011 Proxy Statement, with voting results as follows:
The Companys stockholders voted to approve, on an advisory basis, the taking of future advisory votes on the compensation of the Companys Named Executive Officers on an annual basis, with voting results as follows:
The Companys stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2011, with voting results as follows:
(c) Not applicable.
(d) On May 13, 2011, following the Annual Meeting and after considering the results of the vote on the frequency of future advisory votes on named executive officer compensation (the Frequency Vote), the Board determined to hold future advisory votes on the compensation of our named executive officers on an annual basis until the next required Frequency Vote.
Item 9.01 Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.